Iskra Reic, AstraZeneca’s executive vice president of Vaccines and Immune Therapies, speaks during an interview at Reuters Pharma Event in Barcelona, Spain, April 18, 2023. REUTERS/ Albert Gea
Iskra Reic, AstraZeneca’s executive vice president of Vaccines and Immune Therapies, speaks during an interview at Reuters Pharma Event in Barcelona, Spain, April 18, 2023. REUTERS/ Albert Gea